Showing results (1631-1640 of 6,159) with videos related to
Sort By:
Pageof 616
Nature Medicine|January 19, 2021
High-frequency neuromodulation improves obsessive-compulsive behaviorShrey Grover, John A Nguyen, Vighnesh Viswanathan, et al.Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.Nature Medicine|January 20, 2021
Looking beyond COVID-19 vaccine phase 3 trialsJerome H Kim, Florian Marks, John D ClemensNature Medicine|January 22, 2021
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanomaZhuting Hu, Donna E Leet, Rosa L Allesøe, et al.Nature Medicine|January 14, 2021
An algorithmic approach to reducing unexplained pain disparities in underserved populationsEmma Pierson, David M Cutler, Jure Leskovec, et al.Nature Medicine|January 14, 2022
Optimizing risk-based breast cancer screening policies with reinforcement learningAdam Yala, Peter G Mikhael, Constance Lehman, et al.Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.Nature Medicine|December 11, 2021
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populationsLaleh Seyyed-Kalantari, Haoran Zhang, Matthew B A McDermott, et al.Nature Medicine|December 10, 2021
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanomaJulie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.Pageof 616